Dabigatran Etexilate Capsule
Product Images NDC 31722-622

18 FDA label images from Camber Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Dabigatran Etexilate (NDC 31722-622). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dabigartanfigure1 (Dabigartanfigure1)

Dabigartanfigure1 (Dabigartanfigure1)
A data table summarizing major bleeding events on treatment +2 days in a safety set comparing Dabigatran 150 mg to Warfarin across multiple patient subgroups. It includes patient counts, event rates per year, hazard ratios with 95% confidence intervals, and a forest plot illustrating the comparative risk between Dabigatran and Warfarin by subgroup such as age, gender, weight, medical history, and region.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Dabigatran Etexilate showing its molecular arrangement with aromatic rings, ester groups, and amide functionalities.*
FDA Label Image

Dabigartanfigure2 (Dabigartanfigure2)

Dabigartanfigure2 (Dabigartanfigure2)
Line graph titled "aPTT Time Course" showing activated partial thromboplastin time (aPTT in seconds) over time (hours). The graph includes four curves representing different creatinine clearance (CrCl) ranges: ≤ 30 mL/min, >30 and ≤ 50 mL/min, >50 and <80 mL/min, and >80 mL/min. The graph also notes dosing of Dabigatran etexilate capsules as 150 mg BID for CrCl > 30 mL/min and 75 mg BID for CrCl ≤ 30 mL/min.*
FDA Label Image

Dabigartanfigure31 (Dabigartanfigure31)

Dabigartanfigure31 (Dabigartanfigure31)
A pharmacokinetic chart depicting fold changes and 90% confidence intervals for area under curve (AUC) and maximum concentration (Cmax) of Dabigatran Etexilate when coadministered with various P-gp inhibitors and inducers. The x-axis shows change relative to reference, with data points representing different drug interactions over time and dosage variations.*
FDA Label Image

Dabigartanfigure32 (Dabigartanfigure32)

Dabigartanfigure32 (Dabigartanfigure32)
A forest plot showing the fold change and 90% confidence intervals of pharmacokinetic parameters AUC and Cmax for dabigatran etexilate when co-administered with various interacting drugs and time differences. The x-axis represents change relative to reference, ranging from 0.5 to 2.0, comparing drugs such as atorvastatin, clopidogrel, diclofenac, digoxin, enoxaparin, pantoprazole, and ranitidine.*
FDA Label Image

Dabigartanfigure4 (Dabigartanfigure4)

Dabigartanfigure4 (Dabigartanfigure4)
A cumulative probability curve chart comparing Dabigatran Etexilate (DE) at 110 mg and 150 mg twice daily (bid) doses with Warfarin over time from randomization in months. The vertical axis shows estimated cumulative probability, and the horizontal axis shows time in months up to 39 months. The chart includes a legend and subject risk counts for each group at various time points below the graph.*
FDA Label Image

Dabigartanfigure5 (Dabigartanfigure5)

Dabigartanfigure5 (Dabigartanfigure5)
A forest plot chart comparing the hazard ratios (HR) and 95% confidence intervals (CI) for stroke or systemic embolic events (SEE) in patients treated with Dabigatran 150 mg versus Warfarin. The chart includes subgroup analyses by VKA use at entry, age, gender, weight, history of stroke/TIA, diabetes status, CHADS2 score, creatinine clearance, region, and aspirin use at baseline, showing Dabigatran generally associated with lower HRs compared to Warfarin across most subgroups.*
FDA Label Image
FDA Label Image

Camber-logo-2 (Camber Logo 2)

FDA Label Image

Dabigartancontlabel75mg (Dabigartancontlabel75mg)

Dabigartancontlabel75mg (Dabigartancontlabel75mg)
Dabigatran Etexilate Capsules 75 mg label by Camber Pharmaceuticals, Inc. The label indicates each capsule contains 86.48 mg dabigatran etexilate mesylate equivalent to 75 mg dabigatran etexilate. Package holds 60 oral capsules. Storage instructions and warnings appear on the label. NDC 31722-621-60 is shown along with manufacturing details and a barcode.*
FDA Label Image

Dabigartancontcartonlabel75mg (Dabigartancontcartonlabel75mg)

Dabigartancontcartonlabel75mg (Dabigartancontcartonlabel75mg)
Dabigatran Etexilate Capsules 75 mg box label by Camber Pharmaceuticals, Inc. Package contains 60 capsules. Label includes dosage strength, storage instructions, usage warnings, U.S. contact number, medication guide website, manufacturer details, and barcode. Capsules are oral, prescription-only, with instructions to swallow whole and use within 4 months of opening.*
FDA Label Image

Dabigartanblistercartonlabel75mg (Dabigartanblistercartonlabel75mg)

Dabigartanblistercartonlabel75mg (Dabigartanblistercartonlabel75mg)
Packaging label for Dabigatran Etexilate Capsules 75 mg by Camber Pharmaceuticals, Inc. The label indicates 60 unit-dose capsules (10 x 6), with instructions to swallow the capsule whole and a note that the capsules are not substitutable on a mg-to-mg basis with other dabigatran etexilate dosage forms. The label includes storage instructions, blister opening instructions, manufacturer information (Hetero Labs Limited, India), a barcode, NDC 31722-621-32, and a contact number for medication guides.*
FDA Label Image

Dabigartancontlabel110mg (Dabigartancontlabel110mg)

Dabigartancontlabel110mg (Dabigartancontlabel110mg)
Label for Dabigatran Etexilate Capsules 110 mg by Camber Pharmaceuticals, Inc. The label shows the NDC 31722-666-60 and indicates a 60-capsule unit. Instructions include swallowing the capsule whole and using the product within 4 months after opening. Storage instructions and contact information for Hetero Labs Limited, the manufacturer in India, are also provided.*
FDA Label Image

Dabigartancontcartonlabel110mg (Dabigartancontcartonlabel110mg)

Dabigartancontcartonlabel110mg (Dabigartancontcartonlabel110mg)
Packaging label for Dabigatran Etexilate Capsules, 110 mg, from Camber Pharmaceuticals, Inc. The label shows that the product contains 60 capsules per container and is prescription only. It includes dosage instructions to swallow the capsule whole, storage conditions between 20 to 25°C, and a caution to use within 4 months of opening. The label also provides a U.S. contact number and a reference to a medication guide available online. The product is manufactured by Hetero Labs Limited in India.*
FDA Label Image

Dabigartanblistercartonlabel110mg (Dabigartanblistercartonlabel110mg)

Dabigartanblistercartonlabel110mg (Dabigartanblistercartonlabel110mg)
Carton packaging label for Dabigatran Etexilate Capsules 110 mg by Camber Pharmaceuticals, Inc. The label states the product is an oral capsule with 60 (10x6) unit-dose capsules. It includes storage instructions, batch coding area, medication guide notice, and blister opening instructions. Manufactured for Camber Pharmaceuticals and by Hetero Labs Limited, India.*
FDA Label Image

Dabigartancontlabel150mg (Dabigartancontlabel150mg)

Dabigartancontlabel150mg (Dabigartancontlabel150mg)
Label for Dabigatran Etexilate Capsules 150 mg by Camber Pharmaceuticals, Inc. The label states the strength as 150 mg, box contains 60 capsules. Includes storage instructions, usage guidance, barcode, and manufacturer details for Camber Pharmaceuticals, Piscataway, NJ. The label also notes the capsules are not substitutable on a mg-to-mg basis with other dabigatran etexilate forms.*
FDA Label Image

Dabigartancontcartonlabel150mg (Dabigartancontcartonlabel150mg)

Dabigartancontcartonlabel150mg (Dabigartancontcartonlabel150mg)
Box label for Dabigatran Etexilate 150 mg capsules by Camber Pharmaceuticals, Inc. The label includes dosage warnings, storage instructions, safety seals, medication guide contact, manufacturer details, and contains 60 capsules. NDC number 31722-622-60 is shown, along with barcode and licensing information.*
FDA Label Image

Dabigartanblistercartonlabel150mg-1 (Dabigartanblistercartonlabel150mg 1)

Dabigartanblistercartonlabel150mg-1 (Dabigartanblistercartonlabel150mg 1)
Dabigatran Etexilate Capsules 150 mg packaging label from Camber Pharmaceuticals, Inc. The label states 'Dispense with enclosed medication guide' and 'Rx only.' The package contains 60 unit-dose capsules (10 x 6). Storage instructions and blister opening instructions with diagrams are also visible. The label includes the NDC 31722-622-32 and notes manufacturing by Hetero Labs Limited, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.